| 000 | 01794 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513215504.0 | ||
| 264 | 0 | _c20001004 | |
| 008 | 200010s 0 0 eng d | ||
| 022 | _a0165-0327 | ||
| 024 | 7 |
_a10.1016/s0165-0327(99)00140-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBrunello, N | |
| 245 | 0 | 0 |
_aSocial phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. _h[electronic resource] |
| 260 |
_bJournal of affective disorders _cOct 2000 |
||
| 300 |
_a61-74 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAdrenergic beta-Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aAnxiety Disorders _xcomplications |
| 650 | 0 | 4 |
_aBenzodiazepines _xtherapeutic use |
| 650 | 0 | 4 |
_aBrain _xmetabolism |
| 650 | 0 | 4 |
_aCognitive Behavioral Therapy _xmethods |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 |
_aDepressive Disorder, Major _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMonoamine Oxidase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aPhobic Disorders _xcomplications |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 | _aPsychiatric Status Rating Scales |
| 650 | 0 | 4 |
_aReceptors, Serotonin _xmetabolism |
| 650 | 0 | 4 |
_aSelective Serotonin Reuptake Inhibitors _xtherapeutic use |
| 700 | 1 | _aden Boer, J A | |
| 700 | 1 | _aJudd, L L | |
| 700 | 1 | _aKasper, S | |
| 700 | 1 | _aKelsey, J E | |
| 700 | 1 | _aLader, M | |
| 700 | 1 | _aLecrubier, Y | |
| 700 | 1 | _aLepine, J P | |
| 700 | 1 | _aLydiard, R B | |
| 700 | 1 | _aMendlewicz, J | |
| 700 | 1 | _aMontgomery, S A | |
| 700 | 1 | _aRacagni, G | |
| 700 | 1 | _aStein, M B | |
| 700 | 1 | _aWittchen, H U | |
| 773 | 0 |
_tJournal of affective disorders _gvol. 60 _gno. 1 _gp. 61-74 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0165-0327(99)00140-8 _zAvailable from publisher's website |
| 999 |
_c10889287 _d10889287 |
||